2023
1747. Clinical Spectrum of a Large Multi-State U.S. Cohort of Parechovirus Infection in Neonates and Young Infants
Evans A, Filkins L, Custodio H, Daniels E, Kao C, Richardson K, Carrillo-Marquez M, Borré C, Oliveira C, Espinosa C, Bocchini J, Mandelia Y, Mazade M, Santos R, Carr S, Selvarangan R, Kimberlin D. 1747. Clinical Spectrum of a Large Multi-State U.S. Cohort of Parechovirus Infection in Neonates and Young Infants. Open Forum Infectious Diseases 2023, 10: ofad500.1578. PMCID: PMC10678563, DOI: 10.1093/ofid/ofad500.1578.Peer-Reviewed Original ResearchUniversity of Mississippi Medical CenterMulticenter clinical trialHPeV infectionStudy discontinuationClinical trialsYoung infantsMedical CenterIndustry-sponsored clinical trialsSevere HPeV infectionsMedian hospitalization durationBody fluid specimensParechovirus infectionMedian ageU.S. outbreakPediatric patientsClinical spectrumHospitalization durationFluid specimensHuman parechovirusIRB approvalReport mortalityViral testingBiochemical markersBirth historyInterim analysis
2021
Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study
Oliveira CR, Ortiz AM, Sheth SS, Shapiro ED, Niccolai LM. Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study. BMJ Open 2021, 11: e043093. PMID: 33875441, PMCID: PMC8057558, DOI: 10.1136/bmjopen-2020-043093.Peer-Reviewed Case Reports and Technical NotesConceptsHigh-grade cervical lesionsPre-licensure clinical trialsHPV vaccineCase-control studyNumber of dosesClinical trialsFirst human papillomavirus (HPV) vaccineMultivariate conditional logistic regressionNormal Pap test resultsReal-world clinical settingHuman papillomavirus vaccinePap test resultsHPV types 16Time of immunisationReal-world effectivenessConditional logistic regressionInstitutional review boardDate of testingPapillomavirus vaccineCervical lesionsPotential confoundersVaccine programMedical recordsPersistent infectionType 16
2020
Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, Yarbrough A, Abzug MJ, MacBrayne CE, Soma VL, Dulek DE, Vora SB, Waghmare A, Wolf J, Olivero R, Grapentine S, Wattier RL, Bio L, Cross SJ, Dillman NO, Downes KJ, Oliveira CR, Timberlake K, Young J, Orscheln RC, Tamma PD, Schwenk HT, Zachariah P, Aldrich ML, Goldman DL, Groves HE, Rajapakse NS, Lamb GS, Tribble AC, Hersh AL, Thorell EA, Denison MR, Ratner AJ, Newland JG, Nakamura MM. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal Of The Pediatric Infectious Diseases Society 2020, 10: 34-48. PMID: 32918548, PMCID: PMC7543452, DOI: 10.1093/jpids/piaa115.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMechanical ventilationCOVID-19Pediatric infectious disease physiciansInvasive mechanical ventilationSupplemental oxygen requirementInfectious disease physiciansUse of hydroxychloroquineUse of remdesivirNoninvasive mechanical ventilationUse of antiviralsCoronavirus disease 2019Series of teleconferencesPotential antiviral activityLopinavir-ritonavirCritical illnessDisease physiciansMost patientsSupportive careMembrane oxygenationPediatric patientsAntiviral therapyMild courseSevere illnessIll childrenClinical trials